Tonix Pharmaceuticals Holding Corp.
TNXP Healthcare Biotechnology
Tonix Pharmaceuticals Holding Corp.’s revenue for fiscal 2025 (year ended December 2025) was $13.1 million, up 29.8% from fiscal 2024. In the quarter to June 2026, revenue grew 577.9%, EPS grew 36.8% and free cash flow fell 178.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TNXP
Tonix Pharmaceuticals Holding Corp. (TNXP) P/E ratio
Tonix Pharmaceuticals Holding Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 8 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ENGN enGene Therapeutics Inc compare | n/m |
| TNXP Tonix Pharmaceuticals Holding Corp. | n/m |
| FHTX Foghorn Therapeutics Inc. compare | n/m |
| SEER Seer, Inc. compare | n/m |
| LENZ LENZ Therapeutics, Inc. compare | n/m |
| VTVT vTv Therapeutics Inc. compare | n/m |
| GNLX Genelux Corporation compare | n/m |
| INO Inovio Pharmaceuticals, Inc. compare | n/m |
| CYTT Cyteir Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)